Praxis reports Q4 net loss $88.9M; submits two NDAs; cash $926M

Praxis Precision Medicines, Inc.

2025-FY EPS reported -$13.48 vs consensus -$3.16 ▼ miss (-326.2%)

Net loss $88.9M in Q4 2025 ($303.3M FY), vs $58.7M ($182.8M FY) prior year.
Cash and investments $926.1M at Dec 31, 2025; plus $621.2M Jan 2026 offering funds operations into 2028.
Submitted NDAs to FDA for ulixacaltamide (essential tremor) and relutrigine (SCN2A/SCN8A DEEs).
Topline results expected H1 2026 for vormatrigine Phase 3 (POWER1) and elsunersen EMBRAVE Part A.
Board additions: Jeffrey Kindler, Stuart Arbuckle; promoted Sniecinski to COO, Petrou to President R&D.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.